Correction to: Early clinical response to tofacitinib treatment as a predictor of subsequent efficacy: Results from two phase 3 studies of patients with moderate-to-severe plaque psoriasis

Early clinical response as a predictor of subsequent response to tofacitinib treatment: Results from two phase 3 studies of subjects with moderate to severe plaque psoriasis

10.1016/j.jaad.2016.02.956 ◽

2016 ◽

Vol 74 (5) ◽

pp. AB244

Keyword(s):

Clinical Response ◽

Plaque Psoriasis ◽

Treatment Results ◽

Phase 3 ◽

Two Phase ◽

Severe Plaque Psoriasis ◽

Subsequent Response

Early clinical response to tofacitinib treatment as a predictor of subsequent efficacy: Results from two phase 3 studies of patients with moderate-to-severe plaque psoriasis

Journal of Dermatological Treatment ◽

10.1080/09546634.2016.1214671 ◽

2016 ◽

Vol 28 (1) ◽

pp. 3-7 ◽

Cited By ~ 5

Author(s):

Huaming Tan ◽

Hernan Valdez ◽

Chris E.M. Griffiths ◽

Ulrich Mrowietz ◽

Anna Tallman ◽

...

Keyword(s):

Clinical Response ◽

Plaque Psoriasis ◽

Phase 3 ◽

Two Phase ◽

Impact of previous biologic use and failure on efficacy of brodalumab and ustekinumab: A pooled analysis of data from two phase 3 randomized clinical trials in moderate-to-severe plaque psoriasis (AMAGINE-2 and AMAGINE-3)

10.1016/j.jaad.2017.06.065 ◽

2017 ◽

Vol 76 (6) ◽

pp. AB405

Keyword(s):

Clinical Trials ◽

Plaque Psoriasis ◽

Randomized Clinical Trials ◽

Pooled Analysis ◽

Phase 3 ◽

Two Phase ◽

Durability of DLQI Improvements Among Patients with Moderate to Severe Plaque Psoriasis Treated with Certolizumab Pegol: Three-Year Results from Two Phase 3 Trials (CIMPASI-1 and CIMPASI-2)

SKIN The Journal of Cutaneous Medicine ◽

10.25251/skin.4.supp.80 ◽

2020 ◽

Vol 4 (6) ◽

pp. s80

Author(s):

A Blauvelt ◽

RB Warren ◽

K Reich ◽

F Brock ◽

F Fierens ◽

...

Keyword(s):

Plaque Psoriasis ◽

Certolizumab Pegol ◽

Phase 3 ◽

Two Phase ◽

Abstract not available.

Durability of DLQI Improvements Among Patients with Moderate to Severe Plaque Psoriasis Treated with Certolizumab Pegol: Three-Year Results from Two Phase 3 Trials (CIMPASI-1 and CIMPASI-2)

SKIN The Journal of Cutaneous Medicine ◽

10.25251/skin.5.supp.19 ◽

2021 ◽

Vol 5 (1) ◽

pp. s19

Author(s):

A Blauvelt ◽

RB Warren ◽

K Reich ◽

F Brock ◽

F Fierens ◽

...

Keyword(s):

Plaque Psoriasis ◽

Certolizumab Pegol ◽

Phase 3 ◽

Two Phase ◽

Abstract not available.

Efficacy, Safety, and Tolerability of a Halobetasol 0.01%/Tazarotene 0.045% Fixed Combination in the Treatment of Severe Plaque Psoriasis: Post Hoc Analysis of Two Phase 3 Randomized Controlled Trials

SKIN The Journal of Cutaneous Medicine ◽

10.25251/skin.3.supp.29 ◽

2019 ◽

Vol 3 ◽

pp. S29

Author(s):

Mark G Lebwohl ◽

Jeffrey L Sugarman ◽

Linda Stein Gold ◽

Tina Lin ◽

Gina Martin

Keyword(s):

Randomized Controlled Trials ◽

Plaque Psoriasis ◽

Fixed Combination ◽

Controlled Trials ◽

Phase 3 ◽

Two Phase ◽

Severe Plaque Psoriasis ◽

Post Hoc Analysis ◽

Randomized Controlled ◽

Post Hoc

Abstract not available.

Impact of brodalumab on work productivity in patients with moderate-to-severe plaque psoriasis: Analysis of two phase 3 studies

10.1016/j.jaad.2018.05.649 ◽

2018 ◽

Vol 79 (3) ◽

pp. AB158

Keyword(s):

Plaque Psoriasis ◽

Work Productivity ◽

Phase 3 ◽

Two Phase ◽

Median time to treatment response in patients with moderate-to-severe plaque psoriasis treated with brodalumab 210 mg or ustekinumab: A pooled analysis of data from two phase 3 randomized clinical trials (AMAGINE-2 and AMAGINE-3)

10.1016/j.jaad.2017.04.648 ◽

2017 ◽

Vol 76 (6) ◽

pp. AB167

Keyword(s):

Clinical Trials ◽

Treatment Response ◽

Median Time ◽

Plaque Psoriasis ◽

Randomized Clinical Trials ◽

Pooled Analysis ◽

Phase 3 ◽

Two Phase ◽

Time To Treatment ◽

Durable efficacy of risankizumab compared with ustekinumab across subgroups of patients with moderate-to-severe plaque psoriasis: Integrated analysis of two phase 3 trials

10.1016/j.jaad.2019.06.211 ◽

2019 ◽

Vol 81 (4) ◽

pp. AB49

Keyword(s):

Plaque Psoriasis ◽

Integrated Analysis ◽

Phase 3 ◽

Two Phase ◽

Two phase 3 studies of oral tofacitinib in patients with moderate to severe plaque psoriasis: 16-week efficacy and safety results

10.1016/j.jaad.2015.02.275 ◽

2015 ◽

Vol 72 (5) ◽

pp. AB66

Keyword(s):

Plaque Psoriasis ◽

Efficacy And Safety ◽

Phase 3 ◽

Two Phase ◽